Ropanicant , an [alpha]4[beta]2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization

• Published in: Psychopharmacology 2022-07, Vol.239 (7), p.2215
• Main Authors: Nirogi, Ramakrishna, Abraham, Renny, Jayarajan, Pradeep, Goura, Venkatesh, Kallepalli, Rajesh, Medapati, Rajesh babu, Tadiparthi, Jayaprakash
• Format: Article
• Language: English
• Subjects: Analysis; Antidepressants; Behavioral assessment; Care and treatment; Depression, Mental; Identification and classification; Methods; Nicotinic receptors; Properties
• ISSN: 0033-3158
• DOI: 10.1007/s00213-022-06108-6

Rationale Ropanicant (SUVN-911) (3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo (3.1.0) hexane hydrochloride) is a novel [alpha]4[beta]2 nicotinic acetylcholine receptor (nAChR) antagonist being developed for the treatment of depressive disorders. Objectives Pharmacological and neurochemical characterization of Ropanicant to support a potential molecule for the treatment of depressive disorders. Methods Ropanicant was assessed for antidepressant-like activity using the rat forced swimming test (FST) and differential reinforcement of low rate -72 s (DRL-72 s). Alleviation of anhedonia was assessed in chronic mild stress model using sucrose preference test. To understand the mechanism of action, serotonin levels, ionized calcium-binding adaptor molecule 1 (Iba1), and brain-derived neurotrophic factor (BDNF) were determined. The onset of antidepressant-like activity was determined using the reduction in submissive behavior assay. The effects on cognition and sexual functions were assessed using the object recognition task and sexual dysfunction assay respectively. Interaction of Ropanicant, TC-5214, and methyllycaconitine (MLA) with citalopram was investigated individually in mice FST. Results Ropanicant exhibited antidepressant like properties in the FST and DRL-72 s. A significant reduction in anhedonia was observed in the sucrose preference test. Oral administration of Ropanicant produced a significant increase in serotonin and BDNF levels, with a reduction in the Iba1 activity. The onset of antidepressant like effect with Ropanicant was within a week of treatment, and was devoid of cognitive dulling and sexual dysfunction. While Ropanicant potentiated the effect of citalopram in FST, such an effect was not observed with MLA or TC-5214. Conclusions Preclinical studies with Ropanicant support the likelihood of its therapeutic utility in the treatment of depressive disorders.